Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
7(78%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_1
4
44%
Ph phase_2
3
33%
Ph phase_3
2
22%

Phase Distribution

4

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
3(33.3%)
Phase 3Large-scale testing
2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

9

all time

Status Distribution
Active(7)
Completed(2)

Detailed Status

Active, not recruiting5
Completed2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
9
Active
7
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (44.4%)
Phase 23 (33.3%)
Phase 32 (22.2%)

Trials by Status

completed222%
recruiting222%
active_not_recruiting556%

Recent Activity

7 active trials
Showing 5 of 9
active_not_recruitingphase_2

Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

NCT06497504
active_not_recruitingphase_3

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

NCT05630807
active_not_recruitingphase_3

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)

NCT05630820
recruitingphase_1

A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease

NCT07168356
active_not_recruitingphase_1

Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection

NCT05330455
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT06497504Phase 2

Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

Active Not Recruiting
NCT05630807Phase 3

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

Active Not Recruiting
NCT05630820Phase 3

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)

Active Not Recruiting
NCT07168356Phase 1

A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease

Recruiting
NCT05330455Phase 1

Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection

Active Not Recruiting
NCT06537414Phase 2

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Active Not Recruiting
NCT06058390Phase 1

A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants

Completed
NCT06422767Phase 1

Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

Completed
NCT04954859Phase 2

Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

Recruiting

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9